Is it safe for a 72-year-old RA patient with obesity to take GLP-1 medications, and what should be considered?
At 5'1" and over 220 lbs, the BMI would be well above 30, which falls in the obese range. For people with RA, carrying extra body fat can fuel inflammation and make certain RA medications less effective — so weight Show Full Answer
Is it safe for a 72-year-old RA patient with obesity to take GLP-1 medications, and what should be considered?
At 5'1" and over 220 lbs, the BMI would be well above 30, which falls in the obese range. For people with RA, carrying extra body fat can fuel inflammation and make certain RA medications less effective — so weight management is genuinely important.
Recent research looked at GLP-1 drugs (like Ozempic/Wegovy or Mounjaro/Zepbound) in people with RA who were overweight or obese. The results were encouraging:
- Reduced RA disease activity
- Less joint pain
- Lower inflammation markers (like CRP)
- Better cardiovascular health
Importantly, GLP-1 drugs are not currently approved to treat RA, but they may offer added benefits for those already prescribed them for weight management. There are real considerations to keep in mind before starting a GLP-1 medication:
- About one-third of study participants stopped due to gastrointestinal side effects like nausea or stomach upset
- Cost and insurance coverage can be significant barriers
- Age and existing RA treatments may affect how well the medication is tolerated
Regarding pancytopenia specifically — that question falls outside what can be responsibly answered here, as it involves a complex interaction that really needs to be evaluated by a rheumatologist or primary care provider who knows the full medication history.
A doctor can weigh the potential benefits against any risks given age, current RA treatments, and overall health. That conversation is truly the most important next step.
October 18
Join
Your Privacy Choices
